Exosome Technologies Market Value to Reach USD 343.5 Mn by 2031, rising at a CAGR of 24.8%

The reports provide detailed insights into the global C-reactive Protein (CRP) Testing Market and the Exosome Technologies Market. Here's a summary of each:

The global CRP testing market is valued at US$ 3.1 billion in 2022 and is projected to reach over US$ 4.0 billion by 2031, with a projected CAGR of 2.9% from 2023 to 2031.

Download a Sample for Highlights on Market Drivers and Challenges Affecting the Exosome Technologies:

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=65840

Rise in awareness about benefits of exosome-based biomarkers for efficient diagnosis of cancer is anticipated to fuel global exosome technologies market development. However, lack of standards and established guidelines on exosome extraction and production has hampered market expansion. An example is the lack of protocols for production, isolation, and storage of MSC-derived exosomes. Nevertheless, continuous R&D activities in their separation and purification methods are likely to broaden market outlook in the near future.

Increase in awareness about prognostic, diagnostic, and therapeutic aspects of exosome across the healthcare industry is likely to bolster the exosome technologies industry. Recent market trends indicate exosome technologies are rapidly emerging as early-stage diagnostic marker for complex ailments, especially cancer. Rapid increase in adoption of exosomes as novel biomarker for diagnosis and prognosis of chronic diseases, particularly those that have high incidence rate, is likely to accelerate market development.

Key Findings of Study

Rise in Usage of Loaded Cargo Exosomes in Disease Treatment: Based on exosome type, the loaded cargos segment is anticipated to account for the leading market share from 2023 to 2031. Rise in usage of exosomes as drug delivery systems for a range of biological components, such as small molecules, genetic materials, and cytokines, is expected to bolster the segment. Surge in demand for exosome-targeted drug delivery system can be ascribed to better biocompatibility and lower immunogenicity than most nano-delivery systems.
Surge in Demand for Exosome-based Biomarkers for Diagnosis of Diseases: Surge in usage of exosome-based biomarkers for efficient diagnosis of cancer and other chronic diseases is likely to offer lucrative opportunities to companies in the market. Rise in need for novel diagnostic biomarkers for cancer is expected to bolster the market. Based on cell sources, the MSCs (mesenchymal stem cells) segment accounted for leading market share in 2022. Surge in demand for MSC-derived exosomes for the treatment of kidney, liver, heart, immune, and neurological diseases is likely to propel the MSCs segment. Furthermore, considerable research in exploring therapeutic role of mesenchymal stem cell-derived exosomes in regenerative medicine for range of diseases is expected to fuel the segment in the near future.

Market Drivers:

Increase in the prevalence of chronic diseases like cardiovascular diseases, cancer, and autoimmune diseases.

Rise in demand for CRP testing for diagnosis and management of diseases.

Growth in usage of CRP testing in personalized medicine development

Market Challenges:

Lack of standardization in CRP testing, leading to variability in test results.

Key Players: Agilent Technologies, Laboratory Corporation of America Holdings, Thermo Fisher Scientific, Abbott Laboratories, F. Hoffmann-La Roche Ltd., among others.

Market Segmentation: Based on test type (standard CRP test, high-sensitivity CRP test), type of assay (ELISA, immunoturbidimetry, immuno-chromatography, immunofluorescence, others), indication, end-user, and region.

Exosome Technologies Market:
Market Overview: The global exosome technologies market is valued at US$ 47.3 million in 2022 and is projected to surpass US$ 343.5 million by 2031, with a projected CAGR of 24.8% from 2023 to 2031.

Market Drivers:
Increase in prevalence of cancer and chronic diseases.

Demand for non-invasive diagnostic and therapeutic techniques.

Investment in R&D activities and adoption of exosome-based products in drug discovery.

Market Challenges:

High cost of exosome-based products.

Lack of standardization in isolation and purification techniques.

Limited awareness about exosome technologies among healthcare professionals and patients.

Key Players: AEGLE Therapeutics, Aruna Bio, Bio-Techne Corporation, Carmine Therapeutics, Codiak BioSciences, Thermo Fisher Scientific, among others.
Market Segmentation: Based on exosome type (loaded cargos, non-cargo), cell source, application (therapeutics, diagnostics), end-user, and region
.
Get Customized Solution to Meet Your Research Requirements:

https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=65840

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030

USA - Canada Toll Free: 866-552-3453

This release was published on openPR.